Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Danusertib + Fulvestrant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Danusertib | PHA-739358 | ABL1 Inhibitor 8 AURK Inhibitor (Pan) 12 BCR-ABL Inhibitor 32 FGFR1 Inhibitor 28 RET Inhibitor 53 TrkA Receptor Inhibitor 8 | Danusertib (PHA-739358) is a pan-Aurora kinase with additional activity against ABL, FGFR1, RET, TRKA, and BCR-ABL, including the T315I mutant (PMID: 20072840, PMID: 18089710, PMID: 31625025). | |
Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 29 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|